Publication year
2011Source
Journal of Pediatric Hematology/Oncology, 33, 3, (2011), pp. e109-13ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
IQ Healthcare
Clinical Pharmacy
Journal title
Journal of Pediatric Hematology/Oncology
Volume
vol. 33
Issue
iss. 3
Page start
p. e109
Page end
p. 13
Subject
N4i 2: Invasive mycoses and compromised host; N4i 3: Poverty-related infectious diseases NCEBP 13: Infectious diseases and international health; NCEBP 3: Implementation Science; NCEBP 3: Implementation ScienceAbstract
For the treatment of children with acute lymphoblastic leukemia (ALL), Dutch pediatric oncologists use the Dutch Childhood Oncology Group ALL 10 protocol. This protocol is complex, as it comprises many different drug regimens. One of the drugs is asparaginase which is available in different forms with different pharmacokinetics: Escherichia coli asparaginase, Erwinia asparaginase, and pegylated E. coli asparaginase [polyethylene glycol (PEG) asparaginase]. Here, we report the case of a 3-year-old patient treated with ALL who was 8 times erroneously treated with E. coli asparaginase instead of PEG asparaginase. As E. coli asparaginase was administered to the patient in the lower dosage regimen of PEG asparaginase, she was undertreated, but at the end of the treatment the patient was in complete remission. This case report describes the actual course of treatment, the reasons why it went wrong, and possible preventive measures.
This item appears in the following Collection(s)
- Academic publications [205104]
- Faculty of Medical Sciences [81055]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.